Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Take a brief audio tour around Scrip's Five Must-Know Things, in this episode covering key developments in the business week ended 11 September 2020.
In focus this time are a high-profile pause in a closely-watched coronavirus vaccine trial, one CEO's views on the pricing of COVID-19 interventions, a big Chinese oncology deal, promising results in asthma and an update on the fast-evolving migraine market.
Stories mentioned in this episode:
(Also see "AZ Exercises Caution With COVID Vaccine Safety Pause As Questions Remain Over Vector" - Scrip, 9 Sep, 2020.)
(Also see "Merck CEO Stresses Need For ‘Fair Return’ On COVID-19 Interventions" - Scrip, 7 Sep, 2020.)
(Also see "$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map" - Scrip, 4 Sep, 2020.)
(Also see "Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma" - Scrip, 8 Sep, 2020.)
(Also see "Migraine Market Update: CGRP Inhibitors Slowly Gain Ground" - Scrip, 7 Sep, 2020.)